{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Davis AA"],"funding":["Lynn Sage Cancer Research Foundation","National Institutes of Health"],"pagination":["104316"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637866"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["86"],"pubmed_abstract":["<h4>Background</h4>Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic differences among patients with ILC, invasive ductal carcinoma (IDC), and mixed histology.<h4>Methods</h4>We retrospectively analysed 980 clinically annotated patients (121 ILC, 792 IDC, and 67 mixed histology) from three academic centers with ctDNA evaluation by Guardant360™. Single nucleotide variations (SNVs), copy number variations (CNVs), and oncogenic pathways were compared across histologies.<h4>Findings</h4>ILC was significantly associated with HR+ HER2 negative and HER2 low. SNVs were higher in patients with ILC compared to IDC or mixed his"],"journal":["EBioMedicine"],"pubmed_title":["Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer."],"pmcid":["PMC9637866"],"funding_grant_id":["UL1TR001422"],"pubmed_authors":["Reduzzi C","Bose R","Clifton K","Bagegni NA","Medford AJ","Gradishar WJ","Cristofanilli M","Ma CX","Hensing WL","Ademuyiwa FO","Behdad A","Bucheit L","Velimirovic M","Denault EN","Zhang Q","Bardia A","Gerratana L","D'Amico P","Opyrchal M","Shah AN","Dai CS","Davis AA"],"additional_accession":[]},"is_claimable":false,"name":"Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.","description":"<h4>Background</h4>Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic differences among patients with ILC, invasive ductal carcinoma (IDC), and mixed histology.<h4>Methods</h4>We retrospectively analysed 980 clinically annotated patients (121 ILC, 792 IDC, and 67 mixed histology) from three academic centers with ctDNA evaluation by Guardant360™. Single nucleotide variations (SNVs), copy number variations (CNVs), and oncogenic pathways were compared across histologies.<h4>Findings</h4>ILC was significantly associated with HR+ HER2 negative and HER2 low. SNVs were higher in patients with ILC compared to IDC or mixed his","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-06-01T03:30:19.777Z","creation":"2025-02-19T00:31:40.672Z"},"accession":"S-EPMC9637866","cross_references":{"pubmed":["36332363"],"doi":["10.1016/j.ebiom.2022.104316"]}}